- Current report filing (8-K)
July 07 2010 - 5:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
July 6,
2010
ImmunoGen, Inc.
(Exact name of registrant as specified in its charter)
Massachusetts
|
|
0-17999
|
|
04-2726691
|
(State or other
jurisdiction of
incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer
Identification No.)
|
830 Winter Street, Waltham, MA 02451
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code:
(781) 895-0600
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions (
see
General
Instruction A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
ITEM 8.01. OTHER EVENTS
Genentech,
a member of the Roche Group, and Roche simultaneously announced on the evening
of July 6/morning of July 7, 2010, respectively, the companys
submission of a Biologics License Application, or BLA, to the US Food and Drug
Administration to gain marketing approval in the US of trastuzumab-DM1, or
T-DM1, to treat patients with advanced HER2-positive breast cancer who had
previously received multiple chemotherapies and HER2-targeted medicines. The
basis of the submission is the Phase II trial that was reported at the San
Antonio Breast Cancer Symposium in December 2009.
T-DM1
consists of ImmunoGen, Inc.s DM1 cancer-cell killing agent attached to
Roches HER2-targeting antibody, trastuzumab, using ImmunoGens linker and
methods of attachment. T-DM1 is in global development by Roche under a
collaboration agreement between Genentech and ImmunoGen.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ImmunoGen, Inc.
|
|
(Registrant)
|
|
|
Date:
July 7, 2010
|
/s/
Gregory D. Perry
|
|
|
|
Gregory
D. Perry
|
|
Senior
Vice President and Chief Financial Officer
|
2
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024